The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR-mutant (EGFRm) NSCLC.
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Divya Gupta
No Relationships to Disclose
 
Misako Nagasaka
Stock and Other Ownership Interests - MBrace Therapeutics
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb USA; Caris Life Sciences; Daiichi Sankyo; Genentech; Johnson and Johnson; Lilly; Pfizer; Regeneron; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Johnson and Johnson; Pfizer; Takeda
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Jonathan Riess
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; Foundation Medicine; Genentech; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck; Natera; Nuvalent, Inc.; Nuvation Bio; Oncohost; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Verastem
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Bicycle Therapeutics (Inst); Blossom Hill (Inst); Boehringer Ingelheim (Inst); IO Biotech (Inst); Merck (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Summit pharmaceuticals (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; IO Biotech
 
James Chih Hsin Yang
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Janssen Oncology; Merck KGaA; MSD Oncology; Takeda
 
Julia Rotow
Honoraria - AstraZeneca; Daiichi Sankyo; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blossom Hill; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daiichi Sankyo; EMD Serono; Gilead Sciences; Johnson & Johnson/Janssen; Merus; Novocure; Nuvalent, Inc.; Nuvation Bio; Pfizer; Sanofi/Regeneron; Summit Therapeutics; Takeda
Research Funding - Abbvie (Inst); Altor BioScience (Inst); AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Blossom Hill (Inst); Blueprint Medicines (Inst); Bristol-Myer Squibb; Daiichi Sankyo (Inst); DualityBio (Inst); Enliven Therapeutics (Inst); EpimAb (Inst); ImmunityBio (Inst); Loxo (Inst); ORIC Pharmaceuticals (Inst); RedCloud Biotech (Inst); Regeneron (Inst); Summit Therapeutics (Inst); Synthekine (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Black Diamond Therapeutics; BMS; Daiichi Sankyo; Johnson & Johnson/Janssen; Merus
 
Lyudmila Bazhenova
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; Bayer; BMS GmbH & Co. KG; Boehringer Ingelheim; Genentech/Roche; Janssen Oncology; Lilly; Merck; Natera; Nuvalent, Inc.; Pfizer; Revolution Medicines; Summit pharmaceuticals; Taiho Oncology
 
Molly Li
Honoraria - ACE oncology; Amgen; Anheart Therapeutics; AstraZeneca; BMS; Daiichi Sankyo; Gilead Sciences; Guardant Health; Johnson & Johnson; LiangYiHui Healthcare; Merck KGaA; MSD; Novartis; OncLive; Pfizer; Roche; Takeda; Zai Lab
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Blossomhill Therapeutics; Boehringer Ingelheim; Daichii Sankyo; Johnson & Johnson/Janssen; MSD; Pfizer; Servier; Takeda; Yuhan; Zai Lab
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; MSD; Pfizer; Roche; Zai Lab
 
Hiroki Izumi
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Kaushal Parikh
Consulting or Advisory Role - AstraZeneca (Inst); ImmunityBio (Inst); Intellisphere (Inst); Regeneron (Inst); Rigel (Inst); Takeda Science Foundation (Inst)
Research Funding - Dragonfly Therapeutics (Inst); Merck (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Vividion Therapeutics (Inst)
Travel, Accommodations, Expenses - Rigel
 
Hidetoshi Hayashi
Honoraria - Abbvie; Amgen; AstraZeneca Japan; BeOne Medicines G.K.; Bristol-Myers Squibb Japan; Chugai Pharma; CMIC Inizio Co., Ltd.; Daiichi Sankyo/UCB Japan; Exact Sciences; Gilead Sciences; Hisamitsu Pharmaceutical; Ishiyaku Publishers,Inc.; Janssen; Kyowa Kirin Co., Ltd; Lilly; Medical Review Co., Ltd.; Merck; MSD K.K; Nikkei Visual Images, Inc.; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Novocure; Ono Pharmaceutical; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Henlius; Innovent Biologics; Janssen; Junshi Pharmaceuticals; Nippon Boehringer Ingelheim; Nippon Kayaku; Novocure K.K.
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Aichi Cancer Network (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Boehringer Pharma GmbH; Bristol Myers Squibb Company (Inst); Chugai Pharma (Inst); Clinical Research Support Center Kyushu (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); EPS Holdings (Inst); Fortrea Japan K.K. (Inst); GlaxoSmithKline K.K. (Inst); ICON Clinical Research GK (Inst); intellim (Inst); IQVIA Services JAPAN K.K (Inst); Janssen (Inst); Japan Breast Cancer Research Group (Inst); Japan Clinical Caner Research Organization (Inst); Kyushu Studygroup of Clinical Cancer (Inst); Lilly Japan (Inst); Mebix, Inc (Inst); Mediscience Planning (Inst); Medpace Japan KK (Inst); Mochida Pharmaceutical Co., Ltd (Inst); MSD K.K. (Inst); National Cancer Center (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novocure K.K. (Inst); Ono Pharmaceutical (Inst); Osaka Gyoumeikan Hospital (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); PPD-SNBL (Inst); Public Health Research Foundation (Inst); Sanofi (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); West Japan Oncology Group (Inst)
Other Relationship - EMC K.K.; Japanese Board of Cancer Therapy; Japanese Society of Medical Oncology; MHLW; The Japanese Society of Internal Medicine
 
Alexander Philipovskiy
Research Funding - Abbvie (Inst); Abbvie (Inst); Astellas Pharma (Inst); BeiGene (Inst); Frontier Med (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Janssen Research & Development (Inst); Loxo/Lilly (Inst); Monte Rosa Therapeutics (Inst)
 
Chul Kim
Consulting or Advisory Role - AstraZeneca; Bayer; Bicycle Therapeutics; Biothera; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Daiichi Sankyo; Delfi Diagnostics; EMD Serono; Guardant Health; Henlius; Janssen; Mariana Oncology; Molecular Partners; Natera; Nuvation Bio; Oncohost; Onviv; Partner Therapeutics; Pfizer; Pinetree; RayzeBio; Regeneron; Sanofi; Takeda
Research Funding - AstraZeneca; Black Diamond Therapeutics; Blossom Hill; Boehringer Ingelheim; Daiichi Sankyo; EMD Serono; Genentech/Roche; Gilead Sciences; Janssen; Macrogenics; Novartis; ORIC Pharmaceuticals; Regeneron
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeOne Medicines (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Summit Therapeutics (Inst); Zai Lab (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); BlossomHill Therapeutics (Inst); Boehringer Ingelheim (Inst); Boundless Bio (Inst); Bristol-Myers Squibb (Inst); Carisma Therapeutics (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Modex Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); RasCal (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Shanghai Junshi BioSciences (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Systimmune (Inst); Taiho Oncology (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
J. Jean Cui
Employment - BlossomHill Therapeutics, Inc.
Leadership - BlossomHill Therapeutics, Inc.
Stock and Other Ownership Interests - BlossomHill Therapeutics, Inc
Patents, Royalties, Other Intellectual Property - Inventor in BlossomHill Therapeutics patents
 
Jihao Zhou
Employment - BlossomHill Therapeutics, Inc.
Stock and Other Ownership Interests - BlossomHill Therapeutics, Inc.
 
Geoff Oxnard
Employment - BlossomHill Therapeutics; Foundation Medicine; LOXO at Lilly
Stock and Other Ownership Interests - BlossomHill Therapeutics; Roche
 
Alena Zalutskaya
Employment - BlossomHill Therapeutics
Stock and Other Ownership Interests - BlossomHill Therapeutics
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Natera; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Natera (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)